Abstract 40P
Background
This study aimed to examine MRI dynamic contrast-enhanced (DCE) imaging in various histological and molecular biological types of breast cancer.
Methods
To solve the set tasks, a clinical and instrumental examination was carried out of 70 women with a verified diagnosis of breast cancer who were examined and treated at the RSSPMCO&R in 2017–2019. The age of the patients was 26–75 years (mean age - 49.0 ± 2 years).
Results
For luminal A cancer (22 of 70 cases), the following MR signs were revealed: nodular formations more often had an irregular shape - 21 (95.5%), irregular (59.1%), less often spicular contours (27.3%). In 16 of 22 cases, a ring-shaped contrasting pattern was noted. Type III intensity-time curve at MRI with DCE was found in all 22 patients with luminal A subtype of breast cancer. It should be noted that all additional MR signs (retraction of the nipple, thickening and deformation of the skin over the formation) were found in luminal subtype A. The luminal B-subtype was detected in 20 patients (28.6%), with Her2/neu-positive luminal B-subtype noted in 12 patients, and Her2/neu-negative subtype in 8 cases. For these two subtypes of the masses visualized on MRI images were the same (irregular shape with indistinct contours, annular contrasting), but 4 of 12 patients with luminal Her2/neu-positive subtype had type II on MRI with DCE. The same type of curve was observed in 5 out of 11 patients (45.5%) with Her2/neu-positive breast cancer. At the same time, with luminal, subtype, luminal, Her2/neu-negative subtype, and three cases of negative breast cancer, type III of the dynamic contrast curve was always observed. Consequently, type II of the curve was observed only with negative Her2/neu types. In our studies, in 53% of triple-negative subtypes breast cancer was displayed on MR images with a rounded-oval or lobular shape, and in 17.6% with clear smooth (smooth) contours. But type III “intensity - time” curve, noted according to MRI data with DCE, testified to the malignant process in all 17 patients with triple-negative breast cancer.
Conclusions
Our studies have shown that the pathologically determined degree of differentiation of breast cancer and immunohistochemical types and subtypes affect the visualized morphological characteristics and its functional features, assessed by MRI with DCE.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Nishanova Yulduz.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
260P - A phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL)
Presenter: Yuqin Song
Session: e-Poster Display Session
261P - Clinical outcomes of early-progressed follicular lymphoma in Korea: A multicenter, retrospective analysis
Presenter: Jun Ho Yi
Session: e-Poster Display Session
262P - Correlation between phosphorylated pI3K expression, phosphorylated AKT, and phosphorylated MTOR with serum dehydrogenase lactate level in non-Hodgkin lymphoma
Presenter: Hary Gustian
Session: e-Poster Display Session
263P - Good response to chemotherapy in primary CNS lymphoma may not translate into significant neurocognitive improvement in comatose patients
Presenter: Ryan Lim
Session: e-Poster Display Session
264P - Treatment outcome of primary testicular lymphoma patients treated in tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
271P - Cost-effectiveness of pembrolizumab as monotherapy or in combination with chemotherapy versus EXTREME regimen for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Taiwan
Presenter: Cheng Hsu Wang
Session: e-Poster Display Session
272P - Early metabolic changes in PET metrics over initial 8 weeks of treatment in patients with advanced head neck squamous cell carcinomas treated with chemotherapy
Presenter: Ashish Vaidya
Session: e-Poster Display Session
273P - Long term outcomes of locally advanced & borderline resectable esthesioneuroblastoma and sinonasal tumour with neuroendocrine differentiation treated with neoadjuvant chemotherapy
Presenter: Vikas Talreja
Session: e-Poster Display Session
274P - Comparing comorbidity indices in predicting 90-day mortality after radical radiotherapy for head and neck cancer
Presenter: Therese Tsui
Session: e-Poster Display Session
275P - Weekly paclitaxel, carboplatin and cetuximab (PCC) combination followed by nivolumab in platinum-sensitive recurrent and /or metastatic squamous cell carcinoma of head and neck: A double institution retrospective analysis from India
Presenter: Vivek Agarwala
Session: e-Poster Display Session